New benzimidazoles as thrombopoietin receptor agonists
Igor G Safonov1, Dirk A Heerding, Richard M Keenan
1Medicinal Chemistry and Oncology Research Departments, Microbial, Musculoskeletal and Proliferative Diseases, GlaxoSmithKline Pharmaceuticals, 1250 S. Collegeville Road, Collegeville, PA 19426, USA. igor.2.safonov@gsk.com
Abstract:
A novel benzimidazole series of small-molecule thrombopoietin receptor agonists has been discovered. Herein, we discuss the preliminary exploration of structure-activity relationships within this chemotype.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Anthelminthic Agents
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

